[MO11-2] Association between soluble immune mediators and treatment outcomes for stage III NSCLC patients treated with durvalumab
Abstract password authentication.
The password can be found on page 27 of the program book.
Mini-Oral Session
Thu. Feb 17, 2022 3:00 PM - 3:50 PM Room 8 (Sakura, 1F, Kyoto International Conference Center)
Chair:Hiroaki Okamoto(Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital),Toshiaki Takahashi(Division of Thoracic Oncology, Shizuoka Cancer Center)
Abstract password authentication.
The password can be found on page 27 of the program book.